SOUTH SAN FRANCISCO, Calif., July 7 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that Donald J. Santel, Chief Executive Officer, will provide a company overview at the C.E. Unterberg Conference on Wednesday, July 12, 2006 at 2:06pm ET in New York, New York.
To access the live webcast, please go to www.cotherix.com and click on the “Investor Relations” link. The replay will be available for approximately one week following the presentation.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiovascular disease, including PAH and stable angina. CoTherix currently markets Ventavis(R) (iloprost) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) in the United States in patients with NYHA Class III or IV symptoms (World Health Organization Group I). PAH is a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix, the CoTherix logo and the REVEAL Registry are trademarks of CoTherix, Inc. Ventavis is a trademark of Schering AG, Germany. More information can be found at www.cotherix.com and www.4Ventavis.com.
CoTherix, Inc.
CONTACT: Anne Bowdidge, Senior Director of Investor Relations of CoTherix,Inc., +1-650-808-6551
Web site: http://www.cotherix.com//
